Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study

Purpose: Treatment options are limited after the failure of first-and second-line treatments in patients with HER2+ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human ep...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of gastric cancer 2022, Vol.22 (4), p.408-417
Hauptverfasser:	Zhang, Xin, Huo, Haoran, Nie, Yanan, Xue, Jiadong, Yuan, Zengjiang, Zhang, Zhenyi
Format:	Artikel
Sprache:	kor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!